DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
INDP Indaptus Therapeutics
- 0.799
- +0.016+2.06%
Close Feb 14 16:00 ET
- 0.820
- +0.021+2.62%
Post 19:03 ET
11.28MMarket Cap-0.47P/E (TTM)
0.808High0.740Low33.61KVolume0.751Open0.783Pre Close26.40KTurnover0.30%Turnover RatioLossP/E (Static)14.12MShares3.10052wk High1.88P/B9.08MFloat Cap0.73652wk Low--Dividend TTM11.36MShs Float1600.000Historical High--Div YieldTTM8.69%Amplitude0.736Historical Low0.785Avg Price1Lot Size
Indaptus Therapeutics Stock Forum
Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Wednesday, 5th February at 8:00 am
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical t...
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics has presented interim safety data from its Phase 1 clinical trial of Decoy20 at the SITC 2024 Annual Meeting. The data comes from two cohorts totaling 13 patients receiving single administration and one cohort of 6 patients receiving weekly administration. Results sho...
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025
Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans
NEW YOR...
hey buy
No comment yet